Andrea Zangrando

Andrea Zangrando

Auto-generated profile, based on publicly available information

Andrea Zangrando

Pediatric Hemato Oncology, Maternal and Child Health Department University of Padua Padua Italy

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2011 in Cancer Cell
Verified
Journal Article
Closed access
LMLueder H. Meyer
Lueder H. Meyer
SESarah Mirjam Eckhoff
Sarah Mirjam Eckhoff
MQManon Queudeville
Manon Queudeville
JKJohann Michael Kraus
Johann Michael Kraus
MGMarco Giordan
Marco Giordan
KDKlaus-Michael Debatin
Klaus-Michael Debatin

10 April 2010 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SBSilvia Bresolin
Silvia Bresolin
MZMarco Zecca
Marco Zecca
CFChristian Flotho
Christian Flotho
LTLuca Trentin
Luca Trentin
AZAndrea Zangrando
Andrea Zangrando
GBGiuseppe Basso
Giuseppe Basso
Purpose: Juvenile myelomonocytic leukemia (JMML) is a rare early childhood myelodysplastic/myeloproliferative disorder characterized by an aggressive clinical course. Age and hemoglobin F percentage at diagnosis have been reported to predict both survival and outcome after hematopoietic stem cell transplantation (HSCT). However, no genetic markers with prognostic relevance have been identified so far. We applied gene expression–based classification to JMML samples in order to identify prognostic categories related to clinical outcome.Patients and Methods: Samples of 44 patients with JMML were available for microarray gene expression analysis. A diagnostic classification (DC) model developed for leukemia and myelodysplastic syndrome classification was used to classify the specimens and identify prognostically relevant categories. Statistical analysis was performed to determine the prognostic value of the classification and the genes identifying prognostic categories were further analyzed through R software.Results: The samples could be divided into two major groups: 20 specimens were classified as acute myeloid leukemia (AML) –like and 20 samples as nonAML-like. Four patients could not be assigned to a unique class. The 10-year probability of survival after diagnosis of AML-like and nonAML-like patients was significantly different (7% v 74%; P = .0005). Similarly, the 10-year event-free survival after HSCT was 6% for AML-like and 63% for nonAML-like patients (P = .0010).Conclusion: Gene expression–based classification identifies two groups of patients with JMML with distinct prognosis outperforming all known clinical parameters in terms of prognostic relevance. Gene expression–based classification could thus be prospectively used to guide clinical/therapeutic decisions.

19 September 2008 in Genes, Chromosomes and Cancer
Verified
Journal Article
Open access
PDF file
SBSilvia Bungaro
Silvia Bungaro
MDMarta Campo Dell'Orto
Marta Campo Dell'Orto
AZAndrea Zangrando
Andrea Zangrando
DBDario Basso
Dario Basso
TGTatiana Gorletta
Tatiana Gorletta
GCGiovanni Cazzaniga
Giovanni Cazzaniga
Pediatric acute lymphoblastic leukemia (ALL) comprises genetically distinct subtypes. However, 25% of cases still lack defined genetic hallmarks. To identify genomic aberrancies in childhood ALL patients nonclassifiable by conventional methods, we performed a single nucleotide polymorphisms (SNP) array‐based genomic analysis of leukemic cells from 29 cases. The vast majority of cases analyzed (19/24, 79%) showed genomic abnormalities; at least one of them affected either genes involved in cell cycle regulation or in B‐cell development. The most relevant abnormalities were CDKN2A/9p21 deletions (7/24, 29%), ETV6 (TEL)/12p13 deletions (3/24, 12%), and intrachromosomal amplifications of chromosome 21 (iAMP21) (3/24, 12%). To identify variation in expression of genes directly or indirectly affected by recurrent genomic alterations, we integrated genomic and gene expression data generated by microarray analyses of the same samples. SMAD1 emerged as a down‐regulated gene in CDKN2A homozygous deleted cases compared with nondeleted. The JAG1 gene, encoding the Jagged 1 ligand of the Notch receptor, was among a list of differentially expressed (up‐regulated) genes in ETV6‐deleted cases. Our findings demonstrate that integration of genomic analysis and gene expression profiling can identify genetic lesions undetected by routine methods and potential novel pathways involved in B‐progenitor ALL pathogenesis.

29 May 2015 in Cancer Biology & Therapy
Verified
Journal Article
Open access
MAMarco Agostini
Marco Agostini
AZAndrea Zangrando
Andrea Zangrando
CPChiara Pastrello
Chiara Pastrello
EDEdoardo D'Angelo
Edoardo D'Angelo
GRGabriele Romano
Gabriele Romano
DNDonato Nitti
Donato Nitti
Preoperative chemoradiotherapy is widely used to improve local control of disease, sphincter preservation and to improve survival in patients with locally advanced rectal cancer. Patients enrolled in the present study underwent preoperative chemoradiotherapy, followed by surgical excision. Response to chemoradiotherapy was evaluated according to Mandard's Tumor Regression Grade (TRG). TRG 3, 4 and 5 were considered as partial or no response while TRG 1 and 2 as complete response. From pretherapeutic biopsies of 84 locally advanced rectal carcinomas available for the analysis, only 42 of them showed 70% cancer cellularity at least. By determining gene expression profiles, responders and non-responders showed significantly different expression levels for 19 genes (P < 0.001). We fitted a logistic model selected with a stepwise procedure optimizing the Akaike Information Criterion (AIC) and then validated by means of leave one out cross validation (LOOCV, accuracy = 95%). Four genes were retained in the achieved model: ZNF160, XRCC3, HFM1 and ASXL2. Real time PCR confirmed that XRCC3 is overexpressed in responders group and HFM1 and ASXL2 showed a positive trend. In vitro test on colon cancer resistant/susceptible to chemoradioterapy cells, finally prove that XRCC3 deregulation is extensively involved in the chemoresistance mechanisms. Protein-protein interactions (PPI) analysis involving the predictive classifier revealed a network of 45 interacting nodes (proteins) with TRAF6 gene playing a keystone role in the network. The present study confirmed the possibility that gene expression profiling combined with integrative computational biology is useful to predict complete responses to preoperative chemoradiotherapy in patients with advanced rectal cancer.

2 September 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
MAMarco Agostini
Marco Agostini
KJKlaus-Peter Janssen
Klaus-Peter Janssen
LKLl-Jin Kim
Ll-Jin Kim
EDEdoardo D'Angelo
Edoardo D'Angelo
SPSilvia Pizzini
Silvia Pizzini
SPSalvatore Pucciarelli
Salvatore Pucciarelli
An integrative approach for the identification of prognostic and predictive biomarkers in rectal cancer An integrative approach for the identification of prognostic and predictive biomarkers in rectal cancer

14 March 2021 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
EMEkaterina Mikhailova
Ekaterina Mikhailova
ASAlexandra Semchenkova
Alexandra Semchenkova
OIOlga Illarionova
Olga Illarionova
SKSvetlana Kashpor
Svetlana Kashpor
VBVarvara Brilliantova
Varvara Brilliantova
APAlexander popov
Alexander popov